The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-24. Anything still debated is marked as such rather than presented as settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
B chromosome Any supernumerary nuclear DNA molecule which is not a duplicate of nor homologous to any of the standard complement of normal "A" chromosomes comprising a genome. Typically very small and devoid of structural genes, B chromosomes are by definition not necessary for life. Though they occur naturally in many eukaryotic species, they are not stably inherited and thus vary widely in copy number even between closely related individuals.
=== 1982 World's Fair === In 1974, Downtown Knoxville Association president Stewart Evans, following a discussion with King Cole, president of the 1974 Spokane Exposition, raised the possibility of a similar international exposition for Knoxville. Testerman and Tyree both embraced the fair, though the city council and Knoxvillians in general were initially lukewarm to the idea. One key supporter of the fair was rogue banker Jake Butcher, who in 1975 seized control of Knoxville's largest bank, Hamilton National, and shook up the city's conservative banking community. Following his failed gubernatorial campaign in 1978, Butcher turned his attention to the fair initiative, and helped the city raise critical funding. To prepare for the World's Fair, the merged stretch of I-40 and I-75 in West Knoxville was widened, and I-640 was constructed. The old L&N yard along Second Creek, home to a rough neighborhood known as "Scuffletown," was chosen for the fair site, largely for its redevelopment potential. Three hotel chains— Radisson, Hilton, and Holiday Inn— built large hotels in the downtown area in anticipation of the influx of fair visitors. The fair, officially named the International Energy Exposition, was open from May 1 to October 31, 1982, and drew over 11 million visitors. Its success defied the expectations of the Wall Street Journal, which had derided Knoxville as a "scruffy little town," and had predicted the fair would fail.
==== Wound healing ==== High dose aspirin treatment (which inhibits cyclooxygenases-1 and -2 to block their production of 12-HHT), thromboxane synthase knockout, and BLT2 receptor knockout, but not TXA2 receptor knockout, impair keratinocyte-based re-epithelialization and thereby closure of experimentally induced wounds in mice. A synthetic BLT2 receptor agonist accelerates wound closure not only in this mouse model but also in the db/db mouse model of obesity, diabetes, and dyslipidemia due to leptin receptor deficiency. 12-HHT accumulated in the wounds of the former mouse model. Companion studies using an in vitro scratch test assay indicated that 12-HHT stimulated human and mouse keratinocyte migration by a BLT2 receptor-dependent mechanism that involved the production of tumor necrosis factor α and metalloproteinases. These results indicate that the 12-HHT/BLT2 receptor axis is a critical contributor to wound healing in mice and possibly humans. The axis operates by recruiting the movement of keratinocytes to close the wound. This mechanism may underlie the suppression of wound healing that accompanies the high dose intake of aspirin and, based on mouse studies, other non-steroidal anti-inflammatory agents (NSAIDs) in humans. Synthetic BLT2 agonists may be useful for speeding the healing of chronic ulcerative wounds, particularly in patients with, for example diabetics, that have impaired wound healing.
== Origins of the term == The expression "cold war" was rarely used before 1945. Some writers credit the fourteenth-century Spaniard Don Juan Manuel for first using the term (in Spanish) regarding the conflict between Christianity and Islam; however, the term employed was "tepid" rather than "cold". The word "cold" first appeared in a faulty translation of his work in the 19th century. In 1934, the term was used in reference to a faith healer who received medical treatment after being bitten by a snake. The newspaper report referred to medical staff's suggestion that faith had played a role in his survival as a "truce in the cold war between science and religion". Regarding its contemporary application to a conflict between nation-states, the phrase appears for the first time in English in an anonymous editorial published in The Nation Magazine in March 1938 titled "Hitler's Cold War". The phrase was then used sporadically in newspapers throughout the summer of 1939 to describe the nervous tension and spectre of arms-buildup and mass-conscription prevailing on the European continent (above all in Poland) on the eve of World War II. It was described as either a "cold war" or a "hot peace" in which armies were amassing in many European countries. Graham Hutton, Associate Editor of The Economist, used the term in his essay titled "The Next Peace," published in the August 1939 edition of The Atlantic Monthly (today The Atlantic).
The following list of Quechua ethnic groups is only a selection and delimitations vary. In some cases, these are village communities of just a few hundred people, in other cases ethnic groups of over a million.
Sources: en.wikipedia.org
Amyloid is formed through the polymerization of hundreds to thousands of monomeric peptides or proteins into long fibers. Amyloid formation involves a lag phase (also called nucleation phase), an exponential phase (also called growth phase) and a plateau phase (also called saturation phase), as shown in the figure. When the quantity of fibrils is plotted versus time, a sigmoidal time course is observed reflecting the three distinct phases. In the simplest model of 'nucleated polymerization' (marked by red arrows in the figure below), individual unfolded or partially unfolded polypeptide chains (monomers) convert into a nucleus (monomer or oligomer) via a thermodynamically unfavourable process that occurs early in the lag phase. Fibrils grow subsequently from these nuclei through the addition of monomers in the exponential phase. A different model, called 'nucleated conformational conversion' and marked by blue arrows in the figure below, was introduced later on to fit some experimental observations: monomers have often been found to convert rapidly into misfolded and highly disorganized oligomers distinct from nuclei. Only later on, will these aggregates reorganise structurally into nuclei, on which other disorganised oligomers will add and reorganise through a templating or induced-fit mechanism (this 'nucleated conformational conversion' model), eventually forming fibrils.
In electrical synapses, the presynaptic and postsynaptic cell membranes are connected by special channels called gap junctions that are capable of facilitating the direct flow of electrical current without the need for neurotransmitters, causing voltage changes in the presynaptic cell to induce voltage changes in the postsynaptic cell. In chemical synapses, the activation of voltage-gated calcium channels in the presynaptic neuron results in the release of neurotransmitters into the synaptic cleft, which thereafter bind to receptors located in the plasma membrane of the postsynaptic cell. The neurotransmitter may initiate an electrical response or a secondary messenger pathway that may either excite or inhibit the postsynaptic neuron. Chemical synapses can be classified according to the neurotransmitter released: glutamatergic (often excitatory), GABAergic (often inhibitory), cholinergic (e.g. vertebrate neuromuscular junction), and adrenergic (releasing norepinephrine). Depending on their release location, the receptors they bind to, and the ionic circumstances they encounter, various transmitters can be either excitatory or inhibitory. For instance, acetylcholine can either excite or inhibit depending on the type of receptors it binds to. In excitatory synapses, an influx of Na+ driven by excitatory neurotransmitters opens cation channels, enhancing the probability of depolarization in postsynaptic neurons and the initiation of an action potential.
Martin Keown felt the manager harmed their chances by boasting they could go the season unbeaten. "Look, I said that because I think you can do it. But you must really want it," was Wenger's reply, as he believed the squad had the right mixture of technique, intelligence and physique. Arsenal did little transfer business given the financial demands that came with their new stadium project; their only major signing was Jens Lehmann, who replaced David Seaman as goalkeeper. Wenger retained his best players, despite interest shown by Chelsea's new owner Roman Abramovich. Six games into the league season, Arsenal were involved in a brawl against Manchester United; the ill-feeling stemmed from Vieira's dismissal late on. Several players were charged and fined accordingly by the FA and Wenger apologised for his team's over-reaction. The team restored their image with an entertaining performance against Newcastle; Henry Winter in his match report wrote: "Henry's opening goal encapsulated all that is good about Arsenal, the slick passing and intelligent movement." Wenger led his side to league triumph without a single defeat – an accomplishment last achieved by Preston North End 115 years before, in the Football League. "Somebody threw me a T-shirt after the trophy was presented which read 'Comical Wenger says we can go the whole season unbeaten.' I was just a season too early!," he remarked during the club's victory parade. Arsenal's run of 49 league games unbeaten came to an end with a 2–0 defeat at Manchester United on 24 October 2004.
The city was surrounded by marshes and hills, and Humboldt recorded local stories, including a violent episode involving an acacia tree. Originally planning to cross Panama and sail south, Humboldt learned this route was impractical and instead decided to travel overland through the Andes, which promised rich opportunities for scientific study. This change, like earlier unplanned shifts in his journey, led Humboldt to groundbreaking discoveries in several scientific fields and contributed significantly to his later fame. The journey inland to the eastern Cordilleras began with a nearly 500-mile trip south up the Rio Magdalena, through dense forests to Honda. Humboldt and Bonpland spent over six weeks in a native canoe, hindered by insects, rain, and slow progress against the current. Crew members including Bonpland suffered exhaustion and disease, only Humboldt remained healthy and continued their scientific work. Upon reaching Honda in mid-June, they faced a difficult ascent of 9,000 feet to the plateau of Santa Fé de Bogotá. The road was in poor condition, narrow, and often little more than rock-hewn steps. As they approached Bogotá, their arrival was celebrated with a public procession led by local dignitaries and citizens. Humboldt was honored as a distinguished guest, while the novelty of foreigners attracted public attention. Bonpland’s illness kept them in Bogotá for two months, during which Humboldt received news from Europe, lunched with the Viceroy, studied fossils and minerals, visited Lake Guatavita, and measured mountain heights.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.